RxDoctor Payments Data

Stephanie Martin

Psychiatric/Mental Health · Canton, OHNPI 1427225093

Payments from drug & device makers

$1,732in general payments, 2019–2025

Across 106 payments — averaging $16.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$416
  • Otsuka America Pharmaceutical, Inc.$246
  • AbbVie$245
  • Johnson & Johnson$164
  • Alkermes, Inc.$163
  • Neurocrine Biosciences, Inc.$132
  • plus $365 from 11 others

What the payments were for

  • Food & beverage$1,732100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,732 in reported general payments places this provider in the 70th percentile of 1,808 psychiatric/mental health providers in Ohio.

See all psychiatric/mental health providers in Ohio

Medicare billing

Part B allowed, 2024
$28,311
Medicare patients
66
Services billed
320

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate27$225,970
AustedoDeutetrabenazine30$208,448
Invega SustennaPaliperidone Palmitate60$201,761
VraylarCariprazine Hcl45$67,553
FanaptIloperidone28$45,529
RexultiBrexpiprazole23$41,027
Lurasidone Hcl75$21,391
LybalviOlanzapine/Samidorphan Malate12$16,956
Aripiprazole120$10,075
Paliperidone ErPaliperidone31$8,583
TrintellixVortioxetine Hydrobromide15$7,284
Venlafaxine Hcl ErVenlafaxine Hcl271$6,155
Ziprasidone Hcl67$4,653
Oxcarbazepine79$4,324
Buspirone Hcl248$4,285

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$132$225,97027 claims
Teva Pharmaceuticals USA, Inc.Austedo$416$208,44830 claims
Johnson & JohnsonInvega Sustenna$164$201,76160 claims
AbbVieVraylar$245$67,55345 claims
Vanda Pharmaceuticals Inc.Fanapt$43$45,52928 claims
Otsuka America Pharmaceutical, Inc.Rexulti$246$41,02723 claims
Alkermes, Inc.Lybalvi$163$16,95612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,808 psychiatric/mental health providers in Ohio.

Other psychiatric/mental health in Canton

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →